Live search
TopFind is fetching the latest matches for your search.
We reviewed 12 live results for rituximab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Sumber: Teva Pharmaceuticals
Deskripsi
Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody and was the first FDA-approved biosimilar to Rituxan. It is indicated for adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). The medication is administered as an intravenous (IV) infusion by healthcare professionals and is available in 100 mg/10 mL and 500 mg/50 mL single-dose vials. Teva provides a cost support program for eligible commercially insured patients.
Paling cocok untuk
Adults with Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia treatment, Moderate-to-severe Rheumatoid Arthritis, Patients seeking Rituxan biosimilars and Intravenous infusion therapy
Penilaian
Sumber: Pfizer Inc.
Deskripsi
Ruxience is a biosimilar to the reference product Rituxan (rituximab). It is a prescription biological medicine used for the treatment of adults with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). Administered via intravenous infusion, it is available in 100 mg/10 mL or 500 mg/50 mL single-dose vials. As a monoclonal antibody, it works by targeting the CD20 antigen on the surface of B-cells, facilitating their destruction by the immune system.
Paling cocok untuk
oncology patients, rheumatoid arthritis management, biosimilar therapeutic options and hematologic malignancies
Penilaian
Sumber: Celltrion Healthcare Philippines Inc.
Deskripsi
Truxima is the first oncology monoclonal antibody biosimilar in the Philippines, listed in the Philippine National Formulary for cancer treatment.
Paling cocok untuk
oncology patients, monoclonal antibody therapy and formulary-listed treatments
Penilaian
| Bandingkan | Truxima (rituximab-abbs) | Ruxience (rituximab-pvvr) | Truxima (Rituximab) |
|---|---|---|---|
| Sumber | Teva Pharmaceuticals | Pfizer Inc. | Celltrion Healthcare Philippines Inc. |
| Deskripsi | Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody and was the first FDA-approved biosimilar to Rituxan. It is indicated for adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). The medication is administered as an intravenous (IV) infusion by healthcare professionals and is available in 100 mg/10 mL and 500 mg/50 mL single-dose vials. Teva provides a cost support program for eligible commercially insured patients. | Ruxience is a biosimilar to the reference product Rituxan (rituximab). It is a prescription biological medicine used for the treatment of adults with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). Administered via intravenous infusion, it is available in 100 mg/10 mL or 500 mg/50 mL single-dose vials. As a monoclonal antibody, it works by targeting the CD20 antigen on the surface of B-cells, facilitating their destruction by the immune system. | Truxima is the first oncology monoclonal antibody biosimilar in the Philippines, listed in the Philippine National Formulary for cancer treatment. |
| Paling cocok untuk | Adults with Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia treatment, Moderate-to-severe Rheumatoid Arthritis, Patients seeking Rituxan biosimilars and Intravenous infusion therapy | oncology patients, rheumatoid arthritis management, biosimilar therapeutic options and hematologic malignancies | oncology patients, monoclonal antibody therapy and formulary-listed treatments |
| Tag | |||
| Aksi | Lihat detail | Lihat detail | Lihat detail |
| Penilaian |
Jika Anda ingin memulai dari opsi yang paling seimbang, saya merekomendasikan:
"Truxima (rituximab-abbs) from Teva Pharmaceuticals."
Saya memilih ini karena Truxima is a significant clinical option as the first FDA-approved biosimilar to Rituxan, offering a high-quality, clinically equivalent alternative for treating B-cell malignancies and autoimmune diseases.